Dynamic Technology Lab Private Ltd Acquires 24,738 Shares of Omnicell, Inc. $OMCL

Dynamic Technology Lab Private Ltd lifted its stake in Omnicell, Inc. (NASDAQ:OMCL) by 345.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,890 shares of the company’s stock after acquiring an additional 24,738 shares during the period. Dynamic Technology Lab Private Ltd owned approximately 0.07% of Omnicell worth $971,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in OMCL. Raymond James Financial Inc. bought a new stake in shares of Omnicell during the 2nd quarter valued at $26,000. First Horizon Corp bought a new position in Omnicell in the 3rd quarter worth about $31,000. Farther Finance Advisors LLC grew its holdings in Omnicell by 784.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock valued at $36,000 after buying an additional 1,036 shares in the last quarter. LSV Asset Management purchased a new position in Omnicell during the 3rd quarter valued at about $97,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Omnicell by 385.5% during the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock valued at $146,000 after buying an additional 3,932 shares during the period. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Omnicell

In other news, EVP Corey J. Manley sold 6,106 shares of the firm’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the sale, the executive vice president owned 91,674 shares in the company, valued at approximately $4,574,532.60. This trade represents a 6.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 2.52% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on OMCL. KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective for the company in a research report on Wednesday, January 7th. Piper Sandler reaffirmed an “overweight” rating and set a $49.00 target price (down from $63.00) on shares of Omnicell in a report on Friday, February 6th. Zacks Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a research note on Monday, February 9th. Wells Fargo & Company raised their price target on shares of Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Finally, Wall Street Zen lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Omnicell presently has a consensus rating of “Hold” and a consensus target price of $54.50.

Omnicell Stock Down 2.2%

Shares of NASDAQ OMCL opened at $41.30 on Monday. The company has a current ratio of 1.43, a quick ratio of 1.22 and a debt-to-equity ratio of 0.14. The business has a 50-day moving average of $44.60 and a 200-day moving average of $38.35. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of 1,032.76, a PEG ratio of 1.48 and a beta of 0.79. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.00.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The company had revenue of $313.98 million during the quarter, compared to analysts’ expectations of $313.36 million. During the same period in the prior year, the business earned $0.60 earnings per share. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Sell-side analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.